Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Raw Materials (2016 - 2024)

Corcept Therapeutics' Raw Materials history spans 6 years, with the latest figure at $704000.0 for Q1 2024.

  • For Q1 2024, Raw Materials changed N/A year-over-year to $704000.0; the TTM value through Mar 2024 reached $704000.0, changed N/A, while the annual FY2020 figure was $1.7 million, 21.31% up from the prior year.
  • Raw Materials for Q1 2024 was $704000.0 at Corcept Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.7 million in Q4 2020 and bottomed at $704000.0 in Q1 2024.